secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0000950170-24-058190
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum submits NDA for oral sulopenem; Q1 net loss narrows to $7.1M, cash runway into 2025
--------------------------------------------------------------------------------

- NDA resubmitted in April 2024 for oral sulopenem; FDA action expected early Q4 2024.
- Cash, equivalents & short-term investments $18.2M at March 31, 2024; ATM raised $7.2M in Q1.
- Net loss $7.1M in Q1 2024 vs $9.9M in Q1 2023; non-GAAP net loss $5.8M vs $7.4M.
- R&D expenses fell to $4.0M from $6.4M as REASSURE trial enrollment completed in October 2023.
- Cash runway extended into 2025, including through expected PDUFA date in early Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024058190/0000950170-24-058190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024058190/itrm-20240513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-058190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer